{"filing":{"accession_number":"0001636282-26-000083","cik":"0001636282","ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-15","report_date":null,"primary_document":"syre-20260615.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000083/syre-20260615.htm"},"events":[{"id":10916,"run_id":9576,"accession_number":"0001636282-26-000083","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Spyre Therapeutics announced positive Phase 2 SKYLINE trial topline results for SPY002 in ulcerative colitis, meeting the primary endpoint with a statistically significant 10.7-point RHI reduction (p\u003c0.0001) and demonstrating a favorable safety profile. This material clinical milestone represents a significant development in the company's pipeline that would affect investor assessment of regulatory prospects and commercial value.","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-06-15","form":"8-K","submitted_at":null,"items":[{"id":7353,"accession_number":"0001636282-26-000083","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Spyre announced positive Phase 2 SKYLINE trial topline results for SPY002 in ulcerative colitis on June 15, 2026. While this is clinical trial data rather than financial results, it represents a material development for a clinical-stage biopharmaceutical company that would affect investor assessment of pipeline progress and commercial prospects. This does not fit the earnings_release category (which applies to financial results) but qualifies as material under other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:02:31.112726+00:00","company_name":"","ticker":null,"filing_date":""},{"id":7354,"accession_number":"0001636282-26-000083","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Spyre Therapeutics announced positive Phase 2 clinical trial results for SPY002 in ulcerative colitis, meeting the primary endpoint with a statistically significant 10.7-point RHI reduction (p\u003c0.0001) and favorable safety profile. While this is a material clinical development for a biopharmaceutical company that would affect investor assessment of pipeline value and regulatory prospects, it does not fit the specific \"earnings_release\" category (which typically refers to financial results) and lacks the structured format of a formal earnings announcement. This represents a significant clinical milestone disclosure that is material but best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:02:31.112726+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":7353,"accession_number":"0001636282-26-000083","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"Spyre announced positive Phase 2 SKYLINE trial topline results for SPY002 in ulcerative colitis on June 15, 2026. While this is clinical trial data rather than financial results, it represents a material development for a clinical-stage biopharmaceutical company that would affect investor assessment of pipeline progress and commercial prospects. This does not fit the earnings_release category (which applies to financial results) but qualifies as material under other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:02:31.112726+00:00","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-06-15"},{"id":7354,"accession_number":"0001636282-26-000083","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"Spyre Therapeutics announced positive Phase 2 clinical trial results for SPY002 in ulcerative colitis, meeting the primary endpoint with a statistically significant 10.7-point RHI reduction (p\u003c0.0001) and favorable safety profile. While this is a material clinical development for a biopharmaceutical company that would affect investor assessment of pipeline value and regulatory prospects, it does not fit the specific \"earnings_release\" category (which typically refers to financial results) and lacks the structured format of a formal earnings announcement. This represents a significant clinical milestone disclosure that is material but best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-15T12:02:31.112726+00:00","company_name":"Spyre Therapeutics, Inc.","ticker":"SYRE","filing_date":"2026-06-15"}]}